Literature DB >> 31278112

Treatment of Relapses in ANCA-Associated Vasculitis.

Mark McClure1,2, Rachel B Jones3.   

Abstract

Entities:  

Keywords:  Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antiutrophil Cytoplasmic; Recurrence

Mesh：

Substances：

Year:  2019        PMID： 31278112      PMCID： PMC6625614          DOI： 10.2215/CJN.06250519

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  10 in total

1.  Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Michael Walsh; Oliver Flossmann; Annelies Berden; Kerstin Westman; Peter Höglund; Coen Stegeman; David Jayne
Journal:  Arthritis Rheum       Date:  2012-02

2.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Authors:  John H Stone; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Anthony Turkiewicz; Nadia K Tchao; Lisa Webber; Linna Ding; Lourdes P Sejismundo; Kathleen Mieras; David Weitzenkamp; David Ikle; Vicki Seyfert-Margolis; Mark Mueller; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina A Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Ulrich Specks
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

3.  Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial.

Authors:  Rachel B Jones; Thomas F Hiemstra; Jose Ballarin; Daniel Engelbert Blockmans; Paul Brogan; Annette Bruchfeld; Maria C Cid; Karen Dahlsveen; Janak de Zoysa; Georgína Espigol-Frigolé; Peter Lanyon; Chen Au Peh; Vladimir Tesar; Augusto Vaglio; Michael Walsh; Dorothy Walsh; Giles Walters; Lorraine Harper; David Jayne
Journal:  Ann Rheum Dis       Date:  2019-01-05       Impact factor: 19.103

4.  Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.

Authors:  Rachel B Jones; Shunsuke Furuta; Jan Willem Cohen Tervaert; Thomas Hauser; Raashid Luqmani; Matthew D Morgan; Chen Au Peh; Caroline O Savage; Marten Segelmark; Vladimir Tesar; Pieter van Paassen; Michael Walsh; Kerstin Westman; David Rw Jayne
Journal:  Ann Rheum Dis       Date:  2015-03-04       Impact factor: 19.103

5.  Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease.

Authors:  Darren M Roberts; Rachel B Jones; Rona M Smith; Federico Alberici; Dinakantha S Kumaratne; Stella Burns; David R W Jayne
Journal:  J Autoimmun       Date:  2014-12-31       Impact factor: 7.094

6.  Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.

Authors:  Loïc Guillevin; Christian Pagnoux; Alexandre Karras; Chahera Khouatra; Olivier Aumaître; Pascal Cohen; François Maurier; Olivier Decaux; Jacques Ninet; Pierre Gobert; Thomas Quémeneur; Claire Blanchard-Delaunay; Pascal Godmer; Xavier Puéchal; Pierre-Louis Carron; Pierre-Yves Hatron; Nicolas Limal; Mohamed Hamidou; Maize Ducret; Eric Daugas; Thomas Papo; Bernard Bonnotte; Alfred Mahr; Philippe Ravaud; Luc Mouthon
Journal:  N Engl J Med       Date:  2014-11-06       Impact factor: 91.245

7.  Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.

Authors:  Alexandre Karras; Christian Pagnoux; Marion Haubitz; Kirsten de Groot; Xavier Puechal; Jan Willem Cohen Tervaert; Mårten Segelmark; Loic Guillevin; David Jayne
Journal:  Ann Rheum Dis       Date:  2017-05-25       Impact factor: 19.103

8.  Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.

Authors:  Federico Alberici; Rona M Smith; Rachel B Jones; Darren M Roberts; Lisa C Willcocks; Afzal Chaudhry; Kenneth G C Smith; David R W Jayne
Journal:  Rheumatology (Oxford)       Date:  2014-12-03       Impact factor: 7.580

9.  Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission in Nonlife-Threatening Relapses of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Randomized, Controlled Trial.

Authors:  Janneke Tuin; Patricia M Stassen; Daria I Bogdan; Jan Broekroelofs; Pieter van Paassen; Jan Willem Cohen Tervaert; Jan-Stephan Sanders; Coen A Stegeman
Journal:  Clin J Am Soc Nephrol       Date:  2019-06-28       Impact factor: 8.237

10.  EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis.

Authors:  M Yates; R A Watts; I M Bajema; M C Cid; B Crestani; T Hauser; B Hellmich; J U Holle; M Laudien; M A Little; R A Luqmani; A Mahr; P A Merkel; J Mills; J Mooney; M Segelmark; V Tesar; K Westman; A Vaglio; N Yalçındağ; D R Jayne; C Mukhtyar
Journal:  Ann Rheum Dis       Date:  2016-06-23       Impact factor: 27.973
  10 in total
  4 in total

Review 1.  Diagnostic and Therapeutic Approach in ANCA-Associated Glomerulonephritis: A Review on Management Strategies.

Authors:  Adél Molnár; Péter Studinger; Nóra Ledó
Journal:  Front Med (Lausanne)       Date:  2022-06-03

2.  Association between sinusitis and relapse and changes in the myeloperoxidase-antineutrophil cytoplasmic antibody in microscopic polyangiitis.

Authors:  Hiroya Tanaka; Makoto Yamaguchi; Takayuki Katsuno; Hirokazu Sugiyama; Shiho Iwagaitsu; Hironobu Nobata; Hiroshi Kinashi; Shogo Banno; Takuji Ishimoto; Yasuhiko Ito
Journal:  PLoS One       Date:  2020-12-10       Impact factor: 3.240

3.  Predictors of renal and patient outcomes in anti-neutrophil cytoplasmic antibody-associated vasculitis: Our single-center, tertiary care experience.

Authors:  Aysun Toraman; Özgül Soysal Gündüz
Journal:  Arch Rheumatol       Date:  2021-05-11       Impact factor: 1.472

4.  Association between renal-limited vasculitis and relapse of antineutrophil cytoplasmic antibody-associated vasculitis: A single-center retrospective cohort study in Japan.

Authors:  Makoto Yamaguchi; Mayumi Ito; Hirokazu Sugiyama; Shiho Iwagaitsu; Hironobu Nobata; Hiroshi Kinashi; Takayuki Katsuno; Masahiko Ando; Yoko Kubo; Shogo Banno; Yasuhiko Ito; Takuji Ishimoto
Journal:  PLoS One       Date:  2022-09-29       Impact factor: 3.752
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.